Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Johnson & Johnson
- 27 May 2016 Status changed from recruiting to completed.
- 11 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
- 11 Feb 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.